All In Biotech

NDA 019537 · Bayer Hlthcare

Cipro

Ciprofloxacin Hydrochloride · Oral

NovelAccelerated approvalPriority review

Last checked: Nov 20, 2026Latest source record: Sep 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1987

Oct 22, 1987

Approved uses

13

Original approval plus efficacy supplements

Registered trials

364

90 Phase 3, 32 recruiting

FAERS reports

97,364

81,282 serious, 9,759 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS • Fluoroquinolones, including CIPRO ® , have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together [see Warnings and Precautions ( 5.1 )], including: • Tendinitis and tendon rupture [see Warnings and Precautions ( 5.2 )]. • Peripheral neuropathy [see Warnings and Precautions ( 5.3 )]. • Central nervous system effects [see Warnings and Precautions ( 5.4 )]. Discontinue CIPRO immediately and avoid the use of fluoroquinolones, including CIPRO, in patients who experience any of these serious adverse reactions [see Warnings and Precautions ( 5.1 )] . • Fluoroquinolones, including CIPRO, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid CIPRO in...

What it is approved for

From the label in effect Mar 2, 2026.

CIPRO is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated: • Skin and Skin Structure Infections ( 1.1 ) • Bone and Joint Infections ( 1.2 ) • Complicated Intra-Abdominal Infections ( 1.3 ) • Infectious Diarrhea ( 1.4 ) • Typhoid Fever (Enteric Fever) ( 1.5 ) • Uncomplicated Cervical and Urethral Gonorrhea ( 1.6 ) • Inhalational Anthrax post-exposure in adult and pediatric patients ( 1.7) • Plague in adult and pediatric patients ( 1.8 ) • Chronic Bacterial Prostatitis ( 1.9 ) • Lower Respiratory Tract Infections ( 1.10 ) • Acute Exacerbation of Chronic Bronchitis • Urinary Tract Infections ( 1.11 ) • Urinary Tract Infections (UTI) • Acute Uncomplicated Cystitis • Complicated UTI and Pyelonephritis in Pediatric Patients • Acute Sinusitis ( 1.12 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRO and other antibacterial drugs, CIPRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.13 ) 1.1 Skin and Skin Structure Infections CIPRO is indicated in adult patients for treatment of skin and skin structure infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. 1.2 Bone and Joint Infections CIPRO is indicated in adult patients for treatment of bone and joint infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas...

Mechanism: Ciprofloxacin is a member of the fluoroquinolone class of antibacterial agents [see Microbiology ( 12.4 )]. Mechanism of Action The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV (both Type II topoisomerases), which are required for bacterial DNA replication, transcription, repair, and recombination.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 2, 2015 Supplement 83 · Efficacy
  • Jan 7, 2005 Supplement 52 · Efficacy
  • Mar 25, 2004 Supplement 49 · Efficacy · priority review
  • Aug 30, 2000 Supplement 38 · Efficacy · priority review
  • Apr 3, 1998 Supplement 27 · Efficacy
  • Jun 3, 1997 Supplement 29 · Efficacy
  • May 15, 1997 Supplement 16 · Efficacy
  • Oct 10, 1996 Supplement 22 · Efficacy
  • Sep 11, 1996 Supplement 21 · Efficacy
  • Sep 13, 1995 Supplement 19 · Efficacy
  • Jul 21, 1994 Supplement 15 · Efficacy
  • Jul 21, 1994 Supplement 13 · Efficacy
  • Oct 22, 1987 Original approval · Type 1 - New Molecular Entity · priority review
3 products under this application
  • CIPRO · CIPROFLOXACIN HYDROCHLORIDE EQ 750MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • CIPRO · CIPROFLOXACIN HYDROCHLORIDE EQ 250MG BASE · TABLET, ORAL · Prescription · TE AB
  • CIPRO · CIPROFLOXACIN HYDROCHLORIDE EQ 500MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ciprofloxacin" as an intervention, any sponsor and status, largest first.

All 364 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug hypersensitivity6,288
  • pain6,189
  • fatigue6,120
  • nausea5,925
  • diarrhoea5,915
  • arthralgia5,639
  • drug ineffective5,195
  • dyspnoea4,813
  • acute kidney injury4,798
  • off label use4,695
  • chronic kidney disease4,552
  • vomiting4,503

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,014
20051,124
20061,306
20071,287
20081,819
20091,994
20102,250
20113,343
20123,228
20133,178
20143,522
20154,871
20166,922
20175,600
20188,113
20199,947
20207,219
20216,613
20225,320
20235,614
20245,347
20254,735
20262,989

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cipro (Ciprofloxacin)

2024 spending

$383K

Beneficiaries

1,807

2,197 claims

Per beneficiary

$212

$1.47 per unit

View as table
YearSpending
2020$394,551
2021$415,820
2022$387,641
2023$396,416
2024$382,638

Part D: Cipro (Ciprofloxacin HCl)

2024 spending

$38K

Beneficiaries

273

401 claims

Per beneficiary

$141

$5.34 per unit

View as table
YearSpending
2020$69,771
2021$55,411
2022$36,376
2023$28,560
2024$38,390

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,835 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.